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Cervical cancer is considered a preventable disease because it 
has causative agent called Human Papilloma Virus (HPV). HPV 
infection was detected in up to 99% of women with squamous 
cell carcinoma of uterine cervix. Two HPV vaccines are approv­
ed by the U.S. Food and Drug Administration (FDA) and pro­
tect against subtypes 16 and 18. The first, GARDASIL®, was li­
censed in 2006 and is now recommended as a routine vaccina­
tion for girls and women between the ages of 9­26 in the US. 
The second HPV vaccine, CERVARIX®, was licensed in 2009. 
The World Health Organization (WHO) recommends the intro­
duction of HPV vaccination into national immunization pro­
grams (NIP) where prevention of cervical cancer is a public health 
priority and the introduction is programmatically feasible.
 However, until now, there are some doubts about the safety 
of HPV vaccine. For example, the claim that “HPV vaccines 
have an impressive safety profile is only supported by highly 
flawed design of safety trials and is contrary to accumulating 
evidence from vaccine safety surveillance databases and case 
reports which continue to link HPV vaccination to serious ad­
verse outcomes (including death and permanent disabilities)”. 
In June 2013, there were a few reports described as complex re­
gional pain syndrome (CRPS) and other chronic pain following 
HPV vaccination in Japan. After this issue, the safety of HPV vac­
cine rises to the surface again in Korea. 
 Since the introduction of HPV vaccines in the US, adverse 
events related to the vaccination have been reported to US Ad­
verse Experience reporting system (VAERS). The most com­
mon events reported were: Syncope (or fainting)–common af­
ter injections. Of the 12,424 reports of adverse events, 772 (6% 
of all reports) described serious adverse events, including 32 
reports of deaths, the remaining 11,652 (93.8%) were classified 
as non­serious. The 32 death reports were reviewed and there 
was no common pattern to the deaths that would suggest they 
were caused by the vaccine. In cases where there was an autopsy, 
death certificate, or medical records, the cause of death could 
be explained by factors other than the vaccine. Some causes of 
death determined to date include diabetes, viral illness, illicit 
drug use, and heart failure (1). US Vaccine Safety Datalink (VSD) 
active surveillance confirmed no significant risk for any of the 
pre­specified adverse events after vaccination like Guillain­Barre 
Syndrome (GBS), seizures, syncope, appendicitis, stroke, ve­
nous thromboembolism (VTE) and other allergic reactions. A 
total of 600,558 HPV vaccine doses were administered during 
the study period. Also, there was no increase in rate of anaphy­
laxis following HPV vaccine as compared to previous VSD stud­
ies. In the Kaiser Permanente (US managed care organization) 
post­licensure safety study in females showed no association 
between vaccination with GARDASIL® and congenital anoma­
lies, miscarriages/16 pre­specified autoimmune conditions/ 
VTE/Death/any other general safety events. This study showed 
an increase in syncope on day of vaccination associated with 
GARDASIL® (RR [95% CI]: 6.00 [3.91­9.21]), but external Safety 
Review Committee (SRC) determined syncope associated with 
vaccination due to temporal association and clinical plausibili­
ty. Also, this study showed that local skin infection (cellulitis/
abscess) can be possibly associated with GARDASIL® (RR [95% 
CI]: 1.64 [1.17­2.3]), but the SRC concluded the cases are more 
likely to be caused by injection site reactions.
 In a Weekly Epidemiological Record published in February, 
the WHO’s Global Advisory Committee on Vaccine Safety (GA­
CVS) stated that multiple epidemiological studies have demon­
strated no evidence to support any causal link between HPV 
vaccination and the onset of multiple sclerosis (MS) and other 
autoimmune diseases. The committee reviewed the safety of 
HPV vaccines based on data collected in the US, Australia and 
Japan and data submitted HPV vaccine manufacturer and oth­
ers and concluded there was no confirmation of clinical symp­
toms related to GBS, seizure, stroke, VTE, anaphylaxis and al­
lergic reaction, which were suspected as adverse outcomes fol­
lowing HPV vaccination and there were no reports of adverse 
pregnancy outcomes in women after HPV vaccination. In addi­
tion, the committee continues to affirm that available scientific 
evidence does not support any causal link between aluminum 
containing vaccines and any increased risk of disease, as it said 
in 1999, 2002, 2004, and 2012. This is also stated in < Statement 
on the continued safety of HPV vaccination > published in Mar­
ch 2014 (2).
 In HPV vaccine safety study in general population from France 
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with 113 autoimmune disorders (AD) cases, none of the cases 
of GBS was exposed to HPV vaccine. In the main analysis, the 
adjusted OR for quadrivalent HPV (qHPV) vaccination in these 
AD cases and their matched controls was 0.9 (95% CI, 0.5­1.5). 
Therefore, no evidence of an increase in the risk of the studied 
AD was observable following vaccination with GARDASIL with­
in the time periods studied. Also, there was insufficient statisti­
cal power to allow conclusions to be drawn regarding individu­
al AD (3). In a safety study in general population from Denmark 
and Sweden with vaccinated 997,585 girls aged 10­17, the rate 
ratios for 20 of 23 autoimmune events were not significantly in­
creased (4). The rate ratios for five neurological events were not 
significantly increased and there were inverse associations with 
epilepsy and paralysis. There was no association between expo­
sure to qHPV vaccine and VTE. This study found no evidence 
supporting associations between exposure to qHPV vaccine 
and autoimmune, neurological, and venous thromboembolic 
adverse events (4).
 In summary, according to careful examination of the avail­
able evidence, HPV vaccines benefit­risk profile remains favor­
able. While safety concerns about HPV vaccines have been 
raised, these have systematically been investigated: to date, the 
WHO’s GACVS has not found any safety issue that would alter 
any of the current recommendations for the use of the vaccine. 
Based on benefit­risk profile, the Korea Food & Drug Adminis­
tration (KFDA), Korean Society of Obstetrics and Gynecology 
(KSOG), and Korean Society of Gynecologic Oncology (KSGO) 
recommend HPV vaccination to prevent cervical cancer.
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